ScholarWorks@SUNGKYUNKWAN UNIVERSITY

Oncology Research and Treatment

Journal Title

  • Oncology Research and Treatment

ISSN

  • E 2296-5262 | P 2296-5270 | 2296-5262 | 2296-5270

Publisher

  • S. Karger AG
  • Karger

Listed on(Coverage)

JCR2014-2019
SJR1999-2019
CiteScore2014-2019
SCI2014-2019
SCIE2014-2021
CC2016-2021
SCOPUS2017-2020
MEDLINE2016-2021
EMBASE2016-2020

Active

  • Active

    based on the information

    • SCOPUS:2020-10

Country

  • SWITZERLAND

Aime & Scopes

  • Oncology Research and Treatment offers an interdisciplinary forum for cancer research and treatment. Peer-reviewed original and review articles cover a wide range of aspects in medical hematology and oncology, surgical, neurosurgical, gynecological, pediatric and urological oncology, oral and maxillofacial surgery, dermatological oncology, diagnostics, radiation oncology, psychological care, pathology, clinical-translational oncology, biometry, and oncological rehabilitation. Continuous medical education and clinical news form a further focus. Compact and current, Oncology Research and Treatment keeps both clinicians and researchers up to date. Oncology Research and Treatment is addressed to clinicians and practitioners working and researching in the field of hematology and oncology.

Homepage

Article List

1 - 20 out of 47 results.

SCIESCOPUS
Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study

Goldman, JW[Goldman, Jonathan W.]; Garassino, MC[Garassino, Marina Chiara]; Chen, YB[Chen, Yuanbin]; Hotta, K[Hotta, Katsuyuki]; Poltoratskiy, A[Poltoratskiy, Artem]; Hochmair, MJ[Hochmair, Maximilian J.]; Ozguroglu, M[Ozguroglu, Mustafa]; Ji, JH[Ji, Jun Ho]; Statsenko, G[Statsenko, Galina]; Voitko, O[Voitko, Oleksandr], et al.

ArticleIssue Date2022CitationONCOLOGY RESEARCH AND TREATMENT, v.45, no.SUPPL 3, pp.161 - 161PublisherKARGER
SCIESCOPUS
Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation

Arnold, D[Arnold, Dirk]; Hammel, P[Hammel, Pascal]; Golan, T[Golan, Talia]; Reni, M[Reni, Michele]; Van Cutsem, E[Van Cutsem, Eric]; Macarulla, T[Macarulla, Teresa]; Hall, MJ[Hall, Michael J.]; Park, JO[Park, Joon Oh]; Hochhauser, D[Hochhauser, Daniel]; Oh, DY[Oh, Do-Youn], et al.

ArticleIssue Date2022CitationONCOLOGY RESEARCH AND TREATMENT, v.45, no.SUPPL 3, pp.91 - 92PublisherKARGER
SCIESCOPUS
Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03

Stein, A[Stein, Alexander]; Lordick, F[Lordick, Florian]; Janjigian, YY[Janjigian, Yelena Y.]; Oh, DY[Oh, Do-Youn]; Lee, KW[Lee, Keun-Wook]; Steeghs, N[Steeghs, Neeltje]; Chao, Y[Chao, Yee]; Di Bartolomeo, M[Di Bartolomeo, Maria]; Garcia, MD[Garcia, Marc Diez]; Mohammad, NH[Mohammad, Nadia Haj], et al.

ArticleIssue Date2022CitationONCOLOGY RESEARCH AND TREATMENT, v.45, no.SUPPL 3, pp.94 - 94PublisherKARGER
SCIESCOPUS
Durability of Efficacy with Selpercatinib in Patients (pts) with RET Fusion plus Non-Small-Cell Lung Cancer (NSCLC)

Drillon, AE[Drillon, Alexander E.]; Subbiah, V[Subbiah, Vivek]; Gautschi, O[Gautschi, Oliver]; Tomasini, P[Tomasini, Pascale]; De Braud, FG[De Braud, Filippo G.]; Solomon, B[Solomon, Benjamin]; Tan, DSW[Tan, Daniel Shao-Weng]; Alonso, G[Alonso, Guzman]; Wolf, J[Wolf, Juergen]; Park, K[Park, Keunchil], et al.

ArticleIssue Date2022CitationONCOLOGY RESEARCH AND TREATMENT, v.45, no.SUPPL 3, pp.150 - 150PublisherKARGER
SCIESCOPUS
Final ALTA-1 Results of Brigatinib (BRG) and Crizotinib (CRZ) in ALK Inhibitor-naive Non-small Cell Lung Cancer (NSCLC)

Griesinger, F[Griesinger, F.]; Camidge, DR[Camidge, D. R.]; Kim, HR[Kim, H. R.]; Ahn, MJ[Ahn, M. -J]; Yang, JC[Yang, J. C.]; Han, JY[Han, J. -Y]; Hochmair, M[Hochmair, M.]; Lee, KH[Lee, K. H.]; Delmonte, A[Delmonte, A.]; Garcia, CMR[Garcia Campelo, M. R.], et al.

ArticleIssue Date2022CitationONCOLOGY RESEARCH AND TREATMENT, v.45, no.SUPPL 2, pp.103 - 104PublisherKARGER
SCIESCOPUS
Current Results on Overall Survival with oral Azacitidine Therapy in Patients with acute Myeloid Leukemia in first Remission after intensive Chemotherapy in the Phase 3 QUAZAR Study

Pfeilstocker, M[Pfeilstoecker, M.]; Wei, AH[Wei, A. H.]; Dohner, H[Doehner, H.]; Sayar, H[Sayar, H.]; Ravandi, F[Ravandi, F.]; Montesinos, P[Montesinos, P.]; Dombret, H[Dombret, H.]; Selleslag, D[Selleslag, D.]; Porkka, K[Porkka, K.]; Jang, JH[Jang, J. H.], et al.

ArticleIssue Date2022CitationONCOLOGY RESEARCH AND TREATMENT, v.45, no.SUPPL 2, pp.66 - 67PublisherKARGER
SCIESCOPUS
Durvalumab (D) +/- Tremelimumab (T) plus Platinum Etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of Patients with Long-term Survival in the CASPIAN Study

Reinmuth, N[Reinmuth, N.]; Goldman, JW[Goldman, J. W.]; Garassino, MC[Garassino, M. C.]; Chen, Y[Chen, Y.]; Hotta, K[Hotta, K.]; Hochmair, MJ[Hochmair, M. J.]; Ozguroglu, M[Ozguroglu, M.]; Ji, JH[Ji, J. H.]; Statsenko, G[Statsenko, G.]; Voitko, O[Voitko, O.], et al.

ArticleIssue Date2022CitationONCOLOGY RESEARCH AND TREATMENT, v.45, no.SUPPL 2, pp.101 - 102PublisherKARGER
SCIESCOPUS
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227

Schumann, C[Schumann, C.]; Paz-Ares, L[Paz-Ares, L.]; Ciuleanu, TE[Ciuleanu, T. -E]; Lee, JS[Lee, J. -S]; Urban, L[Urban, L.]; Caro, RB[Caro, Bernabe R.]; Park, K[Park, K.]; Sakai, H[Sakai, H.]; Ohe, Y[Ohe, Y.]; Nishio, M[Nishio, M.], et al.

ArticleIssue Date2021CitationONCOLOGY RESEARCH AND TREATMENT, v.44, pp.173 - 173PublisherKARGER
SCIESCOPUS
Health-related quality of life with Oral Azacitidine (Oral-AZA) in patients with Acute Myeloid Leukemia (AML) in first remission following Intensive Chemotherapy (IC): Results from the phase 3 QUAZAR AML-001 maintenance trial

Martens, UM[Martens, U. M.]; Roboz, G[Roboz, G.]; Dohner, H[Doehner, H.]; Pocock, C[Pocock, C.]; Dombret, H[Dombret, H.]; Ravandi, F[Ravandi, F.]; Jang, JH[Jang, J. H.]; Selleslag, D[Selleslag, D.]; Mayer, J[Mayer, J.]; Liesveld, J[Liesveld, J.], et al.

ArticleIssue Date2021CitationONCOLOGY RESEARCH AND TREATMENT, v.44, pp.112 - 113PublisherKARGER
SCIESCOPUS
MERMAID-2: Phase 3 study of durvalumab in patients with resected, Stage II-III NSCLC who become MRD plus after curative-intent therapy

Reinmuth, N[Reinmuth, N.]; Spigel, D[Spigel, D.]; Peters, S[Peters, S.]; Ahn, MJ[Ahn, M. J.]; Tsuboi, M[Tsuboi, M.]; Chaft, J[Chaft, J.]; Harpole, D[Harpole, D.]; Barlesi, F[Barlesi, F.]; Abbosh, C[Abbosh, C.]; Mann, H[Mann, H.], et al.

ArticleIssue Date2021CitationONCOLOGY RESEARCH AND TREATMENT, v.44, pp.252 - 253PublisherKARGER
SCIESCOPUS
ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma

Trumper, L[Truemper, L.]; O'Connor, OA[O'Connor, O. A.]; Pro, B[Pro, B.]; Illidge, T[Illidge, T.]; Advani, R[Advani, R.]; Bartlett, NL[Bartlett, N. L.]; Christensen, JH[Christensen, J. H.]; Morschhauser, F[Morschhauser, F.]; Domingo-Domenech, E[Domingo-Domenech, E.]; Rossi, G[Rossi, G.], et al.

ArticleIssue Date2021CitationONCOLOGY RESEARCH AND TREATMENT, v.44, pp.128 - 128PublisherKARGER
SCIESCOPUS
IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)

Galle, P[Galle, P.]; Finn, RS[Finn, R. S.]; Qin, S[Qin, S.]; Ikeda, M[Ikeda, M.]; Ducreux, M[Ducreux, M.]; Kim, TY[Kim, T. -Y]; Lim, HY[Lim, H. Y.]; Kudo, M[Kudo, M.]; Breder, V[Breder, V]; Merle, P[Merle, P.], et al.

ArticleIssue Date2021CitationONCOLOGY RESEARCH AND TREATMENT, v.44, pp.34 - 34PublisherKARGER
SCIESCOPUS
POLO: subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

Arnold, D[Arnold, D.]; Golan, T[Golan, T.]; Hammel, P[Hammel, P.]; Reni, M[Reni, M.]; Van Cutsem, E[Van Cutsem, E.]; Macarulla, T[Macarulla, T.]; Hall, MJ[Hall, M. J.]; Park, JO[Park, J. O.]; Hochhauser, D[Hochhauser, D.]; Oh, DY[Oh, D. -Y], et al.

ArticleIssue Date2021CitationONCOLOGY RESEARCH AND TREATMENT, v.44, pp.221 - 221PublisherKARGER
SCIESCOPUS
Comparative efficacy of Cabozantinib and Ramucirumab after Sorafenib for patients with advanced Hepatocellular Carcinoma and AFP >= 400 ng/ml

Trojan, J[Trojan, J.]; Mollon, P[Mollon, P.]; Daniele, B[Daniele, B.]; Marteau, F[Marteau, F.]; Li, Y[Li, Y.]; Xu, Q[Xu, Q.]; Piscaglia, F[Piscaglia, F.]; Zaucha, R[Zaucha, R.]; Sarker, D[Sarker, D.]; Lim, HY[Lim, H. Y.], et al.

ArticleIssue Date2021CitationONCOLOGY RESEARCH AND TREATMENT, v.44, pp.222 - 223PublisherKARGER
SCIESCOPUS
Early progression in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) vs placebo (P)

Reinacher-Schick, A[Reinacher-Schick, A.]; Macarulla, T[Macarulla, T.]; Kindler, HL[Kindler, H. L.]; Hammel, P[Hammel, P.]; Reni, M[Reni, M.]; Van Cutsem, E[Van Cutsem, E.]; Hall, MJ[Hall, M. J.]; Park, JO[Park, J-O]; Hochhauser, D[Hochhauser, D.]; Arnold, D[Arnold, D.], et al.

ArticleIssue Date2020CitationONCOLOGY RESEARCH AND TREATMENT, v.43, no.SUPPL 4, pp.218 - 219PublisherKARGER
SCIESCOPUS
Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial

Algul, H[Algul, H.]; Reni, M[Reni, M.]; Kindler, HL[Kindler, H. L.]; Hammel, P[Hammel, P.]; Van Cutsem, E[Van Cutsem, E.]; Macarulla, T[Macarulla, T.]; Hall, MJ[Hall, M. J.]; Park, JO[Park, J. O.]; Hochhauser, D[Hochhauser, D.]; Arnold, D[Arnold, D.], et al.

ArticleIssue Date2020CitationONCOLOGY RESEARCH AND TREATMENT, v.43, no.SUPPL 4, pp.216 - 216PublisherKARGER
SCIESCOPUS
Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial

Arnold, D[Arnold, D.]; Hall, MJ[Hall, M. J.]; Golan, T[Golan, T.]; Hammel, P[Hammel, P.]; Reni, M[Reni, M.]; Van Cutsem, E[Van Cutsem, E.]; Macarulla, T[Macarulla, T.]; Park, JO[Park, J. O.]; Hochhauser, D[Hochhauser, D.]; Oh, DY[Oh, D-Y], et al.

ArticleIssue Date2020CitationONCOLOGY RESEARCH AND TREATMENT, v.43, no.SUPPL 4, pp.217 - 217PublisherKARGER
SCIESCOPUS
The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of oral CC-486 in patients with Acute Myeloid Leukemia (AML) in first remission

Dohner, H[Doehner, H.]; Wei, AH[Wei, A. H.]; Pocock, C[Pocock, C.]; Montesinos, P[Montesinos, P.]; Dombret, H[Dombret, H.]; Ravandi, F[Ravandi, F.]; Sayar, H[Sayar, H.]; Jang, JH[Jang, J. H.]; Porkka, K[Porkka, K.]; Selleslag, D[Selleslag, D.], et al.

ArticleIssue Date2020CitationONCOLOGY RESEARCH AND TREATMENT, v.43, no.SUPPL 4, pp.38 - 38PublisherKARGER
SCIESCOPUS
Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study

Grohe, C[Grohe, C.]; Paz-Ares, LG[Paz-Ares, L. G.]; Dvorkin, M[Dvorkin, M.]; Chen, Y[Chen, Y.]; Hotta, K[Hotta, K.]; Trukhin, D[Trukhin, D.]; Statsenko, G[Statsenko, G.]; Hochmair, MJ[Hochmair, M. J.]; Ozguroglu, M[Ozguroglu, M.]; Ji, JH[Ji, J. H.], et al.

ArticleIssue Date2020CitationONCOLOGY RESEARCH AND TREATMENT, v.43, no.SUPPL 4, pp.149 - 149PublisherKARGER
SCIESCOPUS
First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes

Schulz, C[Schulz, C.]; Chen, Y[Chen, Y.]; Paz-Ares, LG[Paz-Ares, L. G.]; Dvorkin, M[Dvorkin, M.]; Trukhin, D[Trukhin, D.]; Reinmuth, N[Reinmuth, N.]; Garassino, MC[Garassino, M. C.]; Statsenko, G[Statsenko, G.]; Voitko, O[Voitko, O.]; Hochmair, MJ[Hochmair, M. J.], et al.

ArticleIssue Date2020CitationONCOLOGY RESEARCH AND TREATMENT, v.43, no.SUPPL 4, pp.144 - 145PublisherKARGER
1 2 3
STATISTICS
Total View :5,443,123
Today View :1,515

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어